Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion

Ophthalmic Surgery Lasers and Imaging

Volumn 44, Issue 1, 2013, Pages 28-33

  Shaikh, Adeel H ^a   Petersen, Michael R ^b   Sisk, Robert A ^a,b   Foster, Robert E ^b   Riemann, Christopher D ^a,b   Miller, Daniel M ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; CIPROFLOXACIN; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HUMAN; IMPLANT; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETINAL THICKNESS; RETROSPECTIVE STUDY; VISUAL ACUITY; VITRECTOMY; CENTRAL MACULAR THICKNESS; COMPARATIVE STUDY; PARS PLANA VITRECTOMY; REVIEW; TREATMENT OUTCOME; DRUG EFFECT; DRUG IMPLANT; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RETINA; RETINA VEIN OCCLUSION; VERY ELDERLY; VITREOUS BODY;

AGED; AGED, 80 AND OVER; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

MLCS; MLOWN;

EID: 84872734462     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/23258160-20121221-09     Document Type: Article

References (18)

1. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2011;118:119-133. doi:10.1016/j.ophtha.2010.04.019
2. Orth DH, Patz A. Retinal branch vein occlusion. Surv Ophthalmol. 1978;22:357-376. doi:10.1016/0039-6257(78)90132-7
3. Central Vein Occlusion Study Group. Central vein occlusion study of photocoagulation therapy: baseline findings. Online J Curr Clin Trials. 1993;Oct14: Doc No 95.
4. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-1146. doi:10.1016/j.ophtha.2010.03.032
5. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25:556-560. doi:10.1097/00006982-200507000-00002
6. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979;77:171-180.
7. Machemer R. Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye. Retina. 1996;16:166-167. doi:10.1097/00006982-199616020-00017
8. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101:190-195.
9. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90:810-816.
10. Chandler DB, Hida T, Sheta S, Proia AD, Machemar R. Improve- ment in the efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol. 1987;225:259-265. doi:10.1007/BF02150144
11. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101-1114. doi:10.1001/archophthalmol.2009.234
12. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-339.
13. Brown DM, Campochiaro PA, Singh R P, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124-1133. doi:10.1016/j.ophtha. 2010.02.022
14. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93:452-456. doi:10.1136/bjo.2008.141085
15. Spaide R F, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147:298-306. doi:10.1016/j.ajo.2008.08.016
16. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007;27:1004-1012. doi:10.1097/IAE. 0b013e3180ed458d
17. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686. doi:10.1016/S0161- 6420(02)01969-3
18. Mehta S, Blinder KJ, Shah GK, Kymes SM, Schlief SL, Grand MG. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010;41:323-329. doi:10.3928/15428877-20100430- 05